Different kinds of lung cancer behave in different ways, suggesting they are fundamentally different diseases. According to a University of Colorado Cancer Center study published in Cancer, the official journal of the American Cancer Society, different subgroups of non-small cell lung cancer (NSCLC) show distinct patterns of spread in the ...

Combination drug therapy may be needed to combat non-small cell lung cancer (NSCLC), according to a study by the Translational Genomics Research Institute (TGen) and Van Andel Research Institute (VARI). The study, "STAT3 is Activated by JAK2 Independent of Key Oncogenic Driver Mutation in Non-Small Cell Lung Carcinoma," was published ...

A report from investigators at the Massachusetts General Hospital (MGH) Cancer Center has defined the role of a recently identified gene abnormality in a deadly form of lung cancer. Tumors driven by rearrangements in the ROS1 gene represent 1 to 2 percent of non-small-cell lung cancers (NSCLC), the leading cause ...

An assay which measures the activity of 14 genes in lung cancer tumors can accurately predict who will respond well to surgery and who will probably die within five years, researchers from the University of California, San Francisco, reported in The Lancet. 80% of lung cancer patients have NSCLC (non-small-cell ...

New research published in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents that block certain microRNAs. The study was led by investigators with the Ohio State University Comprehensive Cancer Center - Arthur G. James ...

Scientists from the University of Colorado Cancer Center have once again advanced the treatment of a specific kind of lung cancer. The team has documented how anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) becomes resistant to a drug targeting the abnormal protein in the cancer. It's ...

Tuberculosis (TB) has been suspected to increase a person's risk of lung cancer because the pulmonary inflammation and fibrosis can induce genetic damage. However, direct evidence of specific genetic changes and the disease have not been extensively reported. Research presented in the February 2012 issue of the International Association ...

According to an investigation published in the recent issue of the Journal of the National Cancer Institute, researchers at Moffitt Cancer Center in Tampa, Florida have discovered that a malignancy-risk gene signature created for breast cancer has predictive and prognostic value for individuals suffering with early stage non-small cell lung ...

The investigational drug ganetespib, a synthetic second-generation Hsp90 inhibitor, slowed the growth of cancer cells taken from non-small cell lung cancer tumors with a mutation in the KRAS gene. The drug was even more active when combined with traditional lung cancer treatments and other investigational targeted therapies, according to preclinical ...

Researchers have developed a method to analyze circulating tumor cells in the blood of patients with non-small cell lung cancer. This method, which can analyze a sample size as small as three cells, may allow clinicians to track cancer progress and treatments and could help them develop new therapies. "We ...

Researchers have begun to identify which mutations and pathway changes lead to lung cancer in never-smokers - a first step in developing potential therapeutic targets. Never-smokers (defined as an individual who smoked fewer than 100 cigarettes in his or her lifetime) are estimated to account for 10 percent of lung ...

Multicentric carcinogenesis with the same genetic mutation appears to occur in lung adenocarcinoma, according to data presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy and Personalized Medicine, held Jan. 8-11, 2012. Data also demonstrated that the EGFR and KRAS genes, which are mutually exclusive, ...